113 related articles for article (PubMed ID: 15735122)
1. Plasma bikunin as a favorable prognostic factor in ovarian cancer.
Matsuzaki H; Kobayashi H; Yagyu T; Wakahara K; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
J Clin Oncol; 2005 Mar; 23(7):1463-72. PubMed ID: 15735122
[TBL] [Abstract][Full Text] [Related]
2. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP
Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer.
Tanaka Y; Kobayashi H; Suzuki M; Kanayama N; Suzuki M; Terao T
Gynecol Oncol; 2004 Sep; 94(3):725-34. PubMed ID: 15350365
[TBL] [Abstract][Full Text] [Related]
4. Could high plasma bikunin predict a favorable outcome in ovarian cancer?
McIntosh M
Nat Clin Pract Oncol; 2005 Oct; 2(10):502-3. PubMed ID: 16205769
[No Abstract] [Full Text] [Related]
5. Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma.
Tanaka Y; Kobayashi H; Suzuki M; Kanayama N; Suzuki M; Yamakawa T; Morishita H; Terao T
Cancer; 2003 Jul; 98(2):424-30. PubMed ID: 12872365
[TBL] [Abstract][Full Text] [Related]
6. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Scorilas A; Borgoño CA; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
J Clin Oncol; 2004 Feb; 22(4):678-85. PubMed ID: 14966091
[TBL] [Abstract][Full Text] [Related]
7. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
8. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW
Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214
[TBL] [Abstract][Full Text] [Related]
9. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
Taylor DD; Lyons KS; Gerçel-Taylor C
Gynecol Oncol; 2002 Mar; 84(3):443-8. PubMed ID: 11855885
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Ca 125 levels during primary therapy.
Markmann S; Gerber B; Briese V
Anticancer Res; 2007; 27(4A):1837-9. PubMed ID: 17649781
[TBL] [Abstract][Full Text] [Related]
11. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
12. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
Han LY; Landen CN; Kamat AA; Lopez A; Bender DP; Mueller P; Schmandt R; Gershenson DM; Sood AK
J Clin Oncol; 2006 Feb; 24(5):755-61. PubMed ID: 16380413
[TBL] [Abstract][Full Text] [Related]
14. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
[TBL] [Abstract][Full Text] [Related]
15. Excretion of bikunin and its fragments in the urine of patients with renal stones.
Suzuki M; Kobayashi H; Kageyama S; Shibata K; Fujie M; Terao T
J Urol; 2001 Jul; 166(1):268-74. PubMed ID: 11435884
[TBL] [Abstract][Full Text] [Related]
16. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
17. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
18. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer.
Nagakawa O; Yamagishi T; Akashi T; Nagaike K; Fuse H
Prostate; 2006 Apr; 66(5):447-52. PubMed ID: 16353247
[TBL] [Abstract][Full Text] [Related]
19. Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.
Kang S; Seo SS; Park SY
J Surg Oncol; 2009 Sep; 100(3):244-7. PubMed ID: 19267361
[TBL] [Abstract][Full Text] [Related]
20. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
